These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37214414)

  • 1. Successful Treatment and Retreatment With Erdafitinib for a Patient With
    Pham C; Lang D; Iams WT
    JTO Clin Res Rep; 2023 May; 4(5):100511. PubMed ID: 37214414
    [No Abstract]   [Full Text] [Related]  

  • 2. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
    McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
    Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
    Tamura R; Yoshihara K; Saito T; Ishimura R; Martínez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T
    Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
    Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
    Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer.
    Dhami J; Hirshfield KM; Ganesan S; Hellmann M; Rojas V; Amorosa JK; Riedlinger GM; Zhong H; Ali SM; Pavlick D; Elvin JA; Rodriguez-Rodriguez L
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29588307
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Raphael A; Dudnik E; Hershkovitz D; Jain S; Olsen S; Soussan-Gutman L; Ben-Shitrit T; Dvir A; Nechushtan H; Peled N; Onn A; Agbarya A; On Behalf Of The Israel Lung Cancer Group
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
    Karkera JD; Cardona GM; Bell K; Gaffney D; Portale JC; Santiago-Walker A; Moy CH; King P; Sharp M; Bahleda R; Luo FR; Alvarez JD; Lorenzi MV; Platero SJ
    Mol Cancer Ther; 2017 Aug; 16(8):1717-1726. PubMed ID: 28416604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
    Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR3-TACC3: A novel gene fusion in cervical cancer.
    Carneiro BA; Elvin JA; Kamath SD; Ali SM; Paintal AS; Restrepo A; Berry E; Giles FJ; Johnson ML
    Gynecol Oncol Rep; 2015 Aug; 13():53-6. PubMed ID: 26425723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
    Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
    PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR3-TACC3 fusion in solid tumors: mini review.
    Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
    Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
    Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
    Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.
    Theelen WS; Mittempergher L; Willems SM; Bosma AJ; Peters DD; van der Noort V; Japenga EJ; Peeters T; Koole K; Šuštić T; Blaauwgeers JL; van Noesel CJ; Bernards R; van den Heuvel MM
    J Pathol Clin Res; 2016 Oct; 2(4):223-233. PubMed ID: 27785367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked.
    Nassar AH; Lundgren K; Pomerantz M; Van Allen E; Harshman L; Choudhury AD; Preston MA; Steele GS; Mouw KW; Wei XX; McGregor BA; Choueiri TK; Bellmunt J; Kwiatkowski DJ; Sonpavde GP
    JCO Precis Oncol; 2018; 2():. PubMed ID: 33604498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
    Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
    Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
    Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.
    Zhou Z; Liu Z; Ou Q; Wu X; Wang X; Shao Y; Liu H; Yang Y
    Cancer Biol Med; 2021 Mar; 18(2):490-501. PubMed ID: 33710807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a degrader against oncogenic fusion protein FGFR3-TACC3.
    Shibata N; Cho N; Koyama H; Naito M
    Bioorg Med Chem Lett; 2022 Mar; 60():128584. PubMed ID: 35085722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.